AstraZeneca Gains FDA Nod for Ultomiris, a Treatment for Managing NMOSD
FDA has approved AstraZeneca's Ultomiris, marking the first and only long-acting C5 complement inhibitor for patients with NMOSD.
https://www.pharmtech.com/view..../astrazeneca-gains-f
Discover the world at Altruu, The Discovery Engine